First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The IND application supports the next phase of development of SBO-154
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
